Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.80 |
| ▸ | TSHR | P16473 | 2/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.80 |
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | RECQL | P46063 | 1/20 | 0.80 |
| ▸ | BLM | P54132 | 1/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.80 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.54 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.54 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzamide SCHEMBL8772889 | 0.90 | PARP1 (0.80) | PARP1TDP1TSHRCYP2C19POLB | |
| Benzamide SCHEMBL29618402 | 0.89 | — | — | |
| Benzamide SCHEMBL30112947 | 0.89 | PARP1 (1.00) | PARP1TDP1TSHRCYP2C19POLB | |
| Benzamide SCHEMBL27963599 | 0.89 | PARP1 (1.00) | PARP1TDP1TSHRCYP2C19POLB | |
| Benzamide SCHEMBL6690447 | 0.89 | PARP1 (1.00) | PARP1TDP1TSHRCYP2C19POLB | |
| Benzamide SCHEMBL16352 | 0.89 | — | — | |
| Benzamide SCHEMBL1222101 | 0.89 | PARP1 (1.00) | PARP1TDP1TSHRCYP2C19POLB | |
| Benzamide SCHEMBL1332331 | 0.89 | — | — | |
| SCHEMBL21755166 | 0.89 | PARP1 (1.00) | PARP1TDP1TSHRCYP2C19POLB | |
| Benzamide SCHEMBL11668921 | 0.89 | PARP1 (1.00) | PARP1TDP1TSHRCYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103201280-A | Compositions and methods for inhibition of the jak pathway | RIGEL PHARMACEUTICALS INC | 2013-07-10 | — | — | CN | claimed |
| US-12577231-B2 | Androgen receptor PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-01-01 | — | — | US | disclosed |
| CN-118344372-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-118255774-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-118255773-A | Substituted straight-chain spiro derivatives | 詹森药业有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-116710453-A | Kinase inhibitors and uses thereof | 璧辰医药技术股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4192582-A1 | KINASE INHIBITORS AND USES THEREOF | ABM Therapeutics Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-101790516-A | Novel substituted piperidones as hsp inducers | TORRENT PHARMACEUTICALS LTD | 2010-07-28 | — | — | CN | disclosed |
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| CN-101448792-A | Compounds that potentiate AMPA receptors and their use in medicine | GLAXO GROUP LTD (GB) | 2009-06-03 | — | — | CN | disclosed |
| CN-101287736-A | Pyrrolopyrimidine derivatives as SYK inhibitors | GLAXO GROUP LTD (GB) | 2008-10-15 | — | — | CN | disclosed |
| EP-1948659-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-07-30 | — | — | EP | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| WO-2007042299-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| CN-1612871-A | Processes and intermediates for preparing benzyl epoxides | ELAN PHARM INC (US) | 2005-05-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | PARP1 2737/4885TDP1 2435/4885TSHR 142/4885 |
| US-20260001865-A1 | ANDROGEN RECEPTOR PROTACS | AR, CRBN, PSMA3 | PARP1 1560/4885TDP1 3307/4885TSHR 465/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | PARP1 538/4885TDP1 382/4885TSHR 4643/4885 |
| US-20230203043-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IKZF3, INTS9, CYP2C9 | PARP1 3206/4885TDP1 3969/4885TSHR 1327/4885 |
| US-12577231-B2 | Androgen receptor PROTACS | AR, CRBN, PSMA3 | PARP1 1560/4885TDP1 3307/4885TSHR 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.